| Year |
Citation |
Score |
| 2024 |
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, ... ... Hylton NM, et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature Medicine. PMID 39277672 DOI: 10.1038/s41591-024-03267-1 |
0.349 |
|
| 2024 |
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, ... ... Hylton NM, et al. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature Medicine. PMID 39277671 DOI: 10.1038/s41591-024-03266-2 |
0.407 |
|
| 2024 |
Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ. Npj Breast Cancer. 10: 71. PMID 39098868 DOI: 10.1038/s41523-024-00677-9 |
0.319 |
|
| 2024 |
Diwanji D, Onishi N, Hathi DK, Lawhn-Heath C, Kornak J, Li W, Guo R, Molina-Vega J, Seo Y, Flavell RR, Heditsian D, Brain S, Esserman LJ, Joe BN, Hylton NM, et al. F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy. Radiology. Imaging Cancer. 6: e230082. PMID 38551406 DOI: 10.1148/rycan.230082 |
0.436 |
|
| 2024 |
Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, et al. Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38470545 DOI: 10.1158/1078-0432.CCR-23-2928 |
0.376 |
|
| 2024 |
Chen CA, Hayward JH, Woodard GA, Ray KM, Starr CJ, Hylton NM, Joe BN, Lee AY. Complete Breast MRI Response to Neoadjuvant Chemotherapy and Prediction of Pathologic Complete Response. Journal of Breast Imaging. 1: 217-222. PMID 38424754 DOI: 10.1093/jbi/wbz028 |
0.502 |
|
| 2024 |
Li W, Partridge SC, Newitt DC, Steingrimsson J, Marques HS, Bolan PJ, Hirano M, Bearce BA, Kalpathy-Cramer J, Boss MA, Teng X, Zhang J, Cai J, Kontos D, Cohen EA, ... ... Hylton NM, et al. Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge. Radiology. Imaging Cancer. 6: e230033. PMID 38180338 DOI: 10.1148/rycan.230033 |
0.509 |
|
| 2023 |
Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, ... ... Hylton NM, et al. Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38109213 DOI: 10.1158/1078-0432.CCR-22-2256 |
0.384 |
|
| 2023 |
Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, Asare SM, Sit L, Matthews JB, Perlmutter J, ... Hylton N, et al. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Reports. Medicine. 101312. PMID 38086377 DOI: 10.1016/j.xcrm.2023.101312 |
0.331 |
|
| 2023 |
Onishi N, Bareng TJ, Gibbs J, Li W, Price ER, Joe BN, Kornak J, Esserman LJ, Newitt DC, Hylton NM. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment. Radiology. Imaging Cancer. 5: e220126. PMID 37505107 DOI: 10.1148/rycan.220126 |
0.473 |
|
| 2023 |
Arasu VA, Habel LA, Achacoso NS, Buist DSM, Cord JB, Esserman LJ, Hylton NM, Glymour MM, Kornak J, Kushi LH, Lewis DA, Liu VX, Lydon CM, Miglioretti DL, Navarro DA, et al. Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study. Radiology. 307: e222733. PMID 37278627 DOI: 10.1148/radiol.222733 |
0.36 |
|
| 2023 |
Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, ... ... Hylton NM, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. PMID 37146605 DOI: 10.1016/j.ccell.2023.04.008 |
0.453 |
|
| 2023 |
Chitalia R, Miliotis M, Jahani N, Tastsoglou S, McDonald ES, Belenky V, Cohen EA, Newitt D, Van't Veer LJ, Esserman L, Hylton N, DeMichele A, Hatzigeorgiou A, Kontos D. Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy. Communications Medicine. 3: 46. PMID 36997615 DOI: 10.1038/s43856-023-00273-1 |
0.406 |
|
| 2023 |
Chung M, Calabrese E, Mongan J, Ray KM, Hayward JH, Kelil T, Sieberg R, Hylton N, Joe BN, Lee AY. Deep Learning to Simulate Contrast-enhanced Breast MRI of Invasive Breast Cancer. Radiology. 306: e239004. PMID 36803003 DOI: 10.1148/radiol.239004 |
0.442 |
|
| 2022 |
Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, ... ... Hylton NM, et al. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. Npj Breast Cancer. 8: 128. PMID 36456573 DOI: 10.1038/s41523-022-00493-z |
0.439 |
|
| 2022 |
Chung M, Calabrese E, Mongan J, Ray KM, Hayward JH, Kelil T, Sieberg R, Hylton N, Joe BN, Lee AY. Deep Learning to Simulate Contrast-enhanced Breast MRI of Invasive Breast Cancer. Radiology. 213199. PMID 36378030 DOI: 10.1148/radiol.213199 |
0.509 |
|
| 2022 |
Li W, Le NN, Onishi N, Newitt DC, Wilmes LJ, Gibbs JE, Carmona-Bozo J, Liang J, Partridge SC, Price ER, Joe BN, Kornak J, Magbanua MJM, Nanda R, LeStage B, ... ... Hylton NM, et al. Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy. Cancers. 14. PMID 36139594 DOI: 10.3390/cancers14184436 |
0.327 |
|
| 2022 |
Chitalia R, Pati S, Bhalerao M, Thakur SP, Jahani N, Belenky V, McDonald ES, Gibbs J, Newitt DC, Hylton NM, Kontos D, Bakas S. Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1. Scientific Data. 9: 440. PMID 35871247 DOI: 10.1038/s41597-022-01555-4 |
0.381 |
|
| 2022 |
Le NN, Li W, Onishi N, Newitt DC, Gibbs JE, Wilmes LJ, Kornak J, Partridge SC, LeStage B, Price ER, Joe BN, Esserman LJ, Hylton NM. Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer. Tomography (Ann Arbor, Mich.). 8: 1208-1220. PMID 35645385 DOI: 10.3390/tomography8030099 |
0.47 |
|
| 2022 |
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher IR, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, ... ... Hylton N, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. PMID 35623341 DOI: 10.1016/j.ccell.2022.05.005 |
0.345 |
|
| 2022 |
Nguyen AA, Onishi N, Carmona-Bozo J, Li W, Kornak J, Newitt DC, Hylton NM. Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response. Tomography (Ann Arbor, Mich.). 8: 891-904. PMID 35448706 DOI: 10.3390/tomography8020072 |
0.479 |
|
| 2022 |
Thakran S, Cohen E, Jahani N, Weinstein SP, Pantalone L, Hylton N, Newitt D, DeMichele A, Davatzikos C, Kontos D. Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial. Translational Oncology. 20: 101411. PMID 35395604 DOI: 10.1016/j.tranon.2022.101411 |
0.426 |
|
| 2022 |
Partridge SC, Steingrimsson J, Newitt DC, Gibbs JE, Marques HS, Bolan PJ, Boss MA, Chenevert TL, Rosen MA, Hylton NM. Impact of Alternate -Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial. Tomography (Ann Arbor, Mich.). 8: 701-717. PMID 35314635 DOI: 10.3390/tomography8020058 |
0.373 |
|
| 2021 |
Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, ... ... Hylton NM, et al. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 breast cancer in the adaptively randomized I-SPY2 trial. Nature Communications. 12: 6428. PMID 34741023 DOI: 10.1038/s41467-021-26019-y |
0.405 |
|
| 2021 |
Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, ... ... Hylton NM, et al. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. Npj Breast Cancer. 7: 131. PMID 34611148 DOI: 10.1038/s41523-021-00337-2 |
0.326 |
|
| 2021 |
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, ... ... Hylton NM, et al. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. Jama Oncology. PMID 34529000 DOI: 10.1001/jamaoncol.2021.3690 |
0.379 |
|
| 2021 |
Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, ... ... Hylton NM, et al. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 203645. PMID 34427465 DOI: 10.1148/radiol.2021203645 |
0.387 |
|
| 2021 |
Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, ... ... Hylton NM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. PMID 34143979 DOI: 10.1016/j.ccell.2021.05.009 |
0.381 |
|
| 2021 |
Liu G, Mitra D, Jones EF, Franc BL, Behr SC, Nguyen A, Bolouri MS, Wisner DJ, Joe BN, Esserman LJ, Hylton NM, Seo Y. Mask-Guided Convolutional Neural Network for Breast Tumor Prognostic Outcome Prediction on 3D DCE-MR Images. Journal of Digital Imaging. PMID 33885991 DOI: 10.1007/s10278-021-00449-y |
0.371 |
|
| 2021 |
Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, ... Hylton N, et al. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. Npj Breast Cancer. 7: 32. PMID 33767190 DOI: 10.1038/s41523-021-00239-3 |
0.376 |
|
| 2021 |
Abel MK, Greenwood H, Kelil T, Guo R, Brabham C, Hylton N, Wong J, Alvarado M, Ewing C, Esserman LJ, Boughey JC, Mukhtar RA. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma. Npj Breast Cancer. 7: 25. PMID 33674614 DOI: 10.1038/s41523-021-00233-9 |
0.418 |
|
| 2021 |
Whisenant JG, Romanoff J, Rahbar H, Kitsch AE, Harvey SM, Moy L, DeMartini WB, Dogan BE, Yang WT, Wang LC, Joe BN, Wilmes LJ, Hylton NM, Oh KY, Tudorica LA, et al. Factors Affecting Image Quality and Lesion Evaluability in Breast Diffusion-weighted MRI: Observations from the ECOG-ACRIN Cancer Research Group Multisite Trial (A6702). Journal of Breast Imaging. 3: 44-56. PMID 33543122 DOI: 10.1093/jbi/wbaa103 |
0.375 |
|
| 2020 |
Hathi DK, Li W, Seo Y, Flavell RR, Kornak J, Franc BL, Joe BN, Esserman LJ, Hylton NM, Jones EF. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET. Scientific Reports. 10: 21930. PMID 33318514 DOI: 10.1038/s41598-020-78865-3 |
0.384 |
|
| 2020 |
Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, Strand F, Onishi N, Nguyen AA, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, ... ... Hylton NM, et al. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. Npj Breast Cancer. 6: 63. PMID 33298938 DOI: 10.1038/s41523-020-00203-7 |
0.304 |
|
| 2020 |
McDonald ES, Romanoff J, Rahbar H, Kitsch AE, Harvey SM, Whisenant JG, Yankeelov TE, Moy L, DeMartini WB, Dogan BE, Yang WT, Wang LC, Joe BN, Wilmes LJ, Hylton NM, et al. Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial. Radiology. 202465. PMID 33201788 DOI: 10.1148/radiol.2020202465 |
0.414 |
|
| 2020 |
Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients. Journal of Breast Imaging. 2: 352-360. PMID 32803155 DOI: 10.1093/Jbi/Wbaa028 |
0.566 |
|
| 2020 |
Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, ... ... Hylton NM, et al. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. Jama Oncology. PMID 32701140 DOI: 10.1001/Jamaoncol.2020.2535 |
0.396 |
|
| 2020 |
Tan ET, Wilmes LJ, Joe BN, Onishi N, Arasu VA, Hylton NM, Marinelli L, Newitt DG. Denoising and Multiple Tissue Compartment Visualization of Multi-b-Valued Breast Diffusion MRI. Journal of Magnetic Resonance Imaging : Jmri. e27268. PMID 32614125 DOI: 10.1002/Jmri.27268 |
0.482 |
|
| 2020 |
Li W, Newitt DC, Yun B, Jones EF, Arasu V, Wilmes LJ, Gibbs J, Nguyen AA, Onishi N, Kornak J, Joe BN, Esserman LJ, Hylton NM. Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer. Tomography (Ann Arbor, Mich.). 6: 216-222. PMID 32548299 DOI: 10.18383/j.tom.2020.00016 |
0.409 |
|
| 2020 |
Newitt DC, Amouzandeh G, Partridge SC, Marques HS, Herman BA, Ross BD, Hylton NM, Chenevert TL, Malyarenko DI. Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial. Tomography (Ann Arbor, Mich.). 6: 177-185. PMID 32548294 DOI: 10.18383/j.tom.2020.00008 |
0.453 |
|
| 2020 |
Nguyen AA, Arasu VA, Strand F, Li W, Onishi N, Gibbs J, Jones EF, Joe BN, Esserman LJ, Newitt DC, Hylton NM. Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy. Tomography (Ann Arbor, Mich.). 6: 101-110. PMID 32548286 DOI: 10.18383/j.tom.2020.00009 |
0.424 |
|
| 2020 |
Malyarenko DI, Newitt DC, Amouzandeh G, Wilmes LJ, Tan ET, Marinelli L, Devaraj A, Peeters JM, Giri S, Vom Endt A, Hylton NM, Partridge SC, Chenevert TL. Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study. Tomography (Ann Arbor, Mich.). 6: 86-92. PMID 32548284 DOI: 10.18383/j.tom.2019.00025 |
0.485 |
|
| 2020 |
Onishi N, Li W, Gibbs J, Wilmes LJ, Nguyen A, Jones EF, Arasu V, Kornak J, Joe BN, Esserman LJ, Newitt DC, Hylton NM. Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial. Tomography (Ann Arbor, Mich.). 6: 77-85. PMID 32548283 DOI: 10.18383/j.tom.2020.00006 |
0.384 |
|
| 2020 |
Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy. Cancers. 12. PMID 32527022 DOI: 10.3390/Cancers12061511 |
0.575 |
|
| 2020 |
Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, ... ... Hylton N, et al. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900510. PMID 32125937 DOI: 10.1200/Jco.19.00510 |
0.313 |
|
| 2020 |
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, ... ... Hylton NM, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. Jama Oncology. PMID 32053137 DOI: 10.1001/Jamaoncol.2019.6650 |
0.488 |
|
| 2020 |
Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Brown-Swigart L, Chien AJ, Delson AL, Gibbs J, Aleshin A, Zimmerman B, Esserman L, Hylton N, Veer Lv'. Abstract A50: Circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) for monitoring and predicting response to neoadjuvant therapy (NAT) in high-risk early breast cancer patients in the I-SPY 2 TRIAL Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Liqbiop20-A50 |
0.509 |
|
| 2020 |
Fahrner-Scott K, Wong JM, Piper M, Ewing C, Alvarado M, Esserman LJ, Hylton N, Mukhtar RA. Abstract PD9-08: Accuracy of ultrasound in evaluating response to neoadjuvant therapy in invasive lobular carcinoma of the breast Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd9-08 |
0.509 |
|
| 2020 |
Arasu VA, Kim P, Li W, Strand F, McHargue C, Jones E, Newitt D, Kornak J, Esserman L, Hylton N. Abstract PD9-06: Additive benefit of MRI background parenchymal enhancement (BPE) to an MRI tumor volume model for predicting pathologic complete response (pCR) to neoadjuvant treatment in ISPY2 Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd9-06 |
0.6 |
|
| 2020 |
Onishi N, Li W, Newitt DC, Harnish R, Gibbs J, Jones EF, Nguyen A, Wilmes L, Joe BN, Campbell MJ, Basu A, Veer LJv, DiMichele A, Yee D, Berry DA, ... ... Hylton NM, et al. Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-Pd9-05 |
0.53 |
|
| 2020 |
Li W, Onishi N, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Joe BN, Sit LS, Yau C, Chien AJ, Price E, Albain KS, Kuritza T, Morley K, Boughey JC, ... ... Hylton NM, et al. Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd9-04 |
0.489 |
|
| 2020 |
Kim P, Greenwood HI, Freimanis RI, Hirst GL, Fischer-Colbrie M, Gibbs J, Hylton NM, Yau C, Hwang ES, Esserman LJ, Mukhtar RA. Abstract P6-16-06: Improved early stratification of invasive cancer risk using MRI in a ductal carcinoma in-situ short-term active surveillance cohort treated with neoadjuvant endocrine therapy Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-16-06 |
0.476 |
|
| 2020 |
Pohlmann PR, Yau C, DeMichele A, Isaacs C, Boughey JC, Hylton N, Melisko ME, Perlmutter J, Rugo HS, Symmans WF, Berry DA, Esserman L. Abstract P6-10-06: Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-10-06 |
0.419 |
|
| 2020 |
Li W, Onishi N, Newitt DC, Harnish R, Jones EF, Wilmes LJ, Gibbs J, Price E, Joe BN, Chien AJ, Berry DA, Boughey JC, Albain KS, Clark AS, Edmiston KK, ... ... Hylton NM, et al. Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-02-01 |
0.525 |
|
| 2020 |
Helsten TL, Lo SS, Yau C, Kalinsky K, Elias AD, Wallace AM, Chien AJ, Lu J, Lang JE, Albain KS, Stringer-Reasor E, Clark AS, Boughey JC, Ellis ED, Yee D, ... ... Hylton NM, et al. Abstract P3-11-02: Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-11-02 |
0.493 |
|
| 2020 |
Liu MC, Robinson PA, Yau C, Wallace AM, Chien AJ, Stringer-Reasor E, Nanda R, Yee D, Albain KS, Boughey JC, Han HS, Elias AD, Kalinsky K, Clark AS, Kemmer K, ... ... Hylton NM, et al. Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P3-09-02 |
0.476 |
|
| 2020 |
Yau C, DeMichele A, Symmans WF, Pusztai L, Yee D, Clark AS, Hatzis C, Matthews JB, Carter J, Chen Y, Cole K, Khazai L, Klein M, Kokh D, Krings G, ... ... Hylton NM, et al. Abstract P2-20-02: Site of recurrence after neoadjuvant therapy: Clues to biology and impact on endpoints Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-20-02 |
0.363 |
|
| 2020 |
Pusztai L, Han HS, Yau C, Wolf D, Wallace AM, Shatsky R, Helsten T, Boughey JC, Haddad T, Stringer-Reasor E, Falkson C, Chien AJ, Mukhtar R, Elias A, Virginia B, ... ... Hylton N, et al. Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct011 |
0.513 |
|
| 2019 |
Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, ... ... Hylton NM, et al. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901027. PMID 32031889 DOI: 10.1200/Jco.19.01027 |
0.507 |
|
| 2019 |
Houghton LC, Jung S, Troisi R, LeBlanc ES, Snetselaar LG, Hylton NM, Klifa C, Van Horn L, Paris K, Shepherd JA, Hoover RN, Dorgan JF. Pubertal timing and breast density in young women: a prospective cohort study. Breast Cancer Research : Bcr. 21: 122. PMID 31727127 DOI: 10.1186/S13058-019-1209-X |
0.479 |
|
| 2019 |
Jahani N, Cohen E, Hsieh MK, Weinstein SP, Pantalone L, Hylton N, Newitt D, Davatzikos C, Kontos D. Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration. Scientific Reports. 9: 12114. PMID 31431633 DOI: 10.1038/S41598-019-48465-X |
0.531 |
|
| 2019 |
Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J, Esserman LJ, Hylton NM. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL. Journal of Magnetic Resonance Imaging : Jmri. PMID 31026118 DOI: 10.1002/Jmri.26770 |
0.481 |
|
| 2019 |
Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. Npj Breast Cancer. 5: 12. PMID 31016232 DOI: 10.1038/s41523-019-0107-9 |
0.465 |
|
| 2019 |
Partridge SC, Newitt DC, Chenevert TL, Rosen MA, Hylton NM. Diffusion-weighted MRI in Multicenter Trials of Breast Cancer. Radiology. 190446. PMID 30938630 DOI: 10.1148/Radiol.2019190446 |
0.535 |
|
| 2019 |
Li W, Newitt D, Yun B, Kornak J, Joe B, Yau C, Abe H, Wolverton D, Crane E, Ward K, Nelson M, Niell B, Drukteinis J, Oh K, Brandt K, ... ... Hylton N, et al. Abstract PD4-03: MRI detection of residual disease following neoadjuvant chemotherapy (NAC) in the I-SPY 2 TRIAL Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd4-03 |
0.559 |
|
| 2019 |
Jones E, Ray K, Mukhtar R, Li W, Franc B, Esserman L, Joe B, Pampaloni M, Hylton N. Abstract P6-01-04: Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P6-01-04 |
0.518 |
|
| 2019 |
Wolf D, Yau C, Wulfkuhle J, Petricoin E, Campbell M, Brown-Swigart L, Hirst G, Asare S, Zhu Z, Lee E, Delson A, Pohlmann P, Hylton N, Liu M, Symmans F, et al. Abstract P3-10-02: Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: Lessons from ˜1000 patients across 10 arms of the I-SPY 2 TRIAL Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P3-10-02 |
0.414 |
|
| 2019 |
Hylton N, Symmans W, Yau C, Li W, Hatzis C, Isaacs C, Albain K, Chen Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, et al. Abstract P2-07-03: Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P2-07-03 |
0.383 |
|
| 2019 |
Fahrner-Scott K, Wong J, Piper M, Ewing C, Alvarado M, Esserman L, Hylton N, Mukhtar R. Abstract P1-15-15: Accuracy of MRI after neoadjuvant therapy for invasive lobular carcinoma of the breast Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P1-15-15 |
0.485 |
|
| 2019 |
Schwab R, Clark AS, Yau C, Hylton N, Li W, Wolfe D, Chien AJ, Wallace AM, Forero-Torres A, Stringer-Reasor E, Nanda R, Jaskowiak N, Boughey J, Haddad T, Han HS, et al. Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct136 |
0.482 |
|
| 2019 |
Chen CA, Hayward JH, Woodard GA, Ray KM, Starr CJ, Hylton NM, Joe BN, Lee AY. Complete Breast MRI Response to Neoadjuvant Chemotherapy and Prediction of Pathologic Complete Response Journal of Breast Imaging. 1: 217-222. DOI: 10.1093/Jbi/Wbz028 |
0.559 |
|
| 2018 |
Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, ... ... Hylton NM, et al. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial. Journal of Magnetic Resonance Imaging : Jmri. PMID 30350329 DOI: 10.1002/Jmri.26539 |
0.841 |
|
| 2018 |
Cochran JM, Busch DR, Leproux A, Zhang Z, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue B, Jiang S, Kaufman PA, Chung SH, ... ... Hylton N, et al. Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. Journal of Biomedical Optics. 24: 1-11. PMID 30338678 DOI: 10.1117/1.Jbo.24.2.021202 |
0.564 |
|
| 2018 |
Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, ... ... Hylton NM, et al. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology. 180273. PMID 30179110 DOI: 10.1148/Radiol.2018180273 |
0.544 |
|
| 2018 |
Hylton NM. Residual Disease after Neoadjuvant Therapy for Breast Cancer: Can MRI Help? Radiology. 181846. PMID 30152746 DOI: 10.1148/Radiol.2018181846 |
0.609 |
|
| 2018 |
Huang SY, Franc BL, Harnish RJ, Liu G, Mitra D, Copeland TP, Arasu VA, Kornak J, Jones EF, Behr SC, Hylton NM, Price ER, Esserman L, Seo Y. Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis. Npj Breast Cancer. 4: 24. PMID 30131973 DOI: 10.1038/s41523-018-0078-2 |
0.471 |
|
| 2018 |
Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, et al. The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. International Journal of Radiation Oncology, Biology, Physics. PMID 29966725 DOI: 10.1016/J.Ijrobp.2018.06.023 |
0.357 |
|
| 2018 |
Jung S, Goloubeva O, Hylton N, Klifa C, LeBlanc E, Shepherd J, Snetselaar L, Van Horn L, Dorgan JF. Intake of dietary carbohydrates in early adulthood and adolescence and breast density among young women. Cancer Causes & Control : Ccc. PMID 29802491 DOI: 10.1007/S10552-018-1040-1 |
0.44 |
|
| 2018 |
Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM, et al. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. Ajr. American Journal of Roentgenology. 1-10. PMID 29708782 DOI: 10.2214/Ajr.17.18323 |
0.531 |
|
| 2018 |
Olshen A, Wolf D, Jones EF, Newitt D, Veer LV', Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. Journal of Medical Imaging (Bellingham, Wash.). 5: 011014. PMID 29296631 DOI: 10.1117/1.Jmi.5.1.011014 |
0.556 |
|
| 2018 |
Newitt DC, Malyarenko D, Chenevert TL, Quarles CC, Bell L, Fedorov A, Fennessy F, Jacobs MA, Solaiyappan M, Hectors S, Taouli B, Muzi M, Kinahan PE, Schmainda KM, Prah MA, ... ... Hylton N, et al. Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network. Journal of Medical Imaging (Bellingham, Wash.). 5: 011003. PMID 29021993 DOI: 10.1117/1.Jmi.5.1.011003 |
0.387 |
|
| 2018 |
Li W, Wilmes L, Newitt D, Jones E, Gibbs J, Poon M, Li E, Partridge S, Kornak J, Esserman L, Hylton N. Abstract P2-09-23: Diffusion-weighted MRI improves imaging prediction of response in the I-SPY 2 trial Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-09-23 |
0.559 |
|
| 2018 |
Hwang E, Duong S, Bedrosian I, Allred J, Wisner D, Hyslop T, Caudle A, Guenther J, Hudis C, Winer E, Esserman L, Hylton N. Abstract GS5-05: Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) CALGB 40903 (Alliance) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Gs5-05 |
0.467 |
|
| 2017 |
Leproux, O'Sullivan TD, Cerussi A, Durkin A, Hill B, Hylton N, Yodh AG, Carp SA, Boas D, Jiang S, Paulsen KD, Pogue B, Roblyer D, Yang W, Tromberg BJ. Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial Journal of Biomedical Optics. 22: 121604. PMID 29389104 DOI: 10.1117/1.Jbo.22.12.121604 |
0.446 |
|
| 2017 |
Ray KM, Kerlikowske K, Lobach IV, Hofmann MB, Greenwood HI, Arasu VA, Hylton NM, Joe BN. Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices. Radiology. 170811. PMID 29072981 DOI: 10.1148/Radiol.2017170811 |
0.415 |
|
| 2017 |
Bane O, Hectors SJ, Wagner M, Arlinghaus LL, Aryal MP, Cao Y, Chenevert TL, Fennessy F, Huang W, Hylton NM, Kalpathy-Cramer J, Keenan KE, Malyarenko DI, Mulkern RV, Newitt DC, et al. Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study. Magnetic Resonance in Medicine. PMID 28913930 DOI: 10.1002/Mrm.26903 |
0.336 |
|
| 2017 |
Nanda R, Liu MC, Yau C, Asare S, Hylton N, Veer LV, Perlmutter J, Wallace AM, Chien AJ, Forero-Torres A, Ellis E, Han H, Sanders Clark A, Albain KS, Caroline Boughey J, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. Journal of Clinical Oncology. 35: 506-506. DOI: 10.1200/Jco.2017.35.15_Suppl.506 |
0.398 |
|
| 2017 |
Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques H, Esserman L, Hylton NM. ACRIN 6698 trial: Quantitative diffusion-weighted MRI to predict pathologic response in neoadjuvant chemotherapy treatment of breast cancer. Journal of Clinical Oncology. 35: 11520-11520. DOI: 10.1200/Jco.2017.35.15_Suppl.11520 |
0.52 |
|
| 2017 |
Wolf D, Yau C, Sanil A, Glas A, Petricoin C, Wulfkuhle J, Brown-Swigart L, Hirst G, Investigators IT, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, et al. Abstract S2-06: DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S2-06 |
0.447 |
|
| 2017 |
Li W, Arasu V, Jones E, Newitt D, Wilmes L, Kornak J, Esserman L, Hylton N. Abstract PD3-05: Effect of MR imaging contrast kinetic thresholds for prediction of neoadjuvant chemotherapy response in breast cancer subtypes – Results from ACRIN 6657 / I-SPY 1 trial Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd3-05 |
0.586 |
|
| 2017 |
Yee D, Paoloni M, Veer Lv, Sanil A, Yau C, Forero A, Chien A, Wallace A, Moulder S, Albain K, Kaplan H, Elias A, Haley B, Boughey J, Kemmer K, ... ... Hylton N, et al. Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-11-04 |
0.515 |
|
| 2017 |
Forero A, Yee D, Buxton M, Symmans W, Chien A, Boughey J, Elias A, DeMichele A, Moulder S, Minton S, Kaplan H, Albain K, Wallace A, Haley B, Isaacs C, ... ... Hylton N, et al. Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-11-02 |
0.519 |
|
| 2017 |
Shah M, Jensen R, Yau C, Straehley I, Berry D, DeMichele A, Buxton M, Hylton N, Perlmutter J, Symmans W, Tripathy D, Yee D, Wallace A, Kaplan H, Clark A, et al. Abstract P5-11-18: Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P5-11-18 |
0.401 |
|
| 2017 |
Singer L, Jones E, Newitt D, Kornak J, Hylton N, Park CC. Dynamic Contrast-Enhanced MRI in Monitoring Changes in Tumor-Associated Stroma During Treatment With Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.482 |
0.551 |
|
| 2016 |
Wilmes LJ, Li W, Shin HJ, Newitt DC, Proctor E, Harnish R, Hylton NM. Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. Tomography : a Journal For Imaging Research. 2: 438-447. PMID 29527574 DOI: 10.18383/j.tom.2016.00271 |
0.366 |
|
| 2016 |
Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical Breast Cancer. PMID 28110902 DOI: 10.1016/J.Clbc.2016.12.008 |
0.516 |
|
| 2016 |
Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography : a Journal For Imaging Research. 2: 378-387. PMID 28066808 DOI: 10.18383/j.tom.2016.00247 |
0.47 |
|
| 2016 |
Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, ... ... Hylton NM, et al. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. Journal of Magnetic Resonance Imaging : Jmri. PMID 27981651 DOI: 10.1002/Jmri.25560 |
0.548 |
|
| 2016 |
Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter P, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman P, Yodh AG, Chung SH, ... ... Hylton N, et al. Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging (DOSI). Cancer Research. PMID 27527559 DOI: 10.1158/0008-5472.Can-16-0346 |
0.572 |
|
| 2016 |
Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, et al. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. The New England Journal of Medicine. 375: 23-34. PMID 27406347 DOI: 10.1056/Nejmoa1513749 |
0.512 |
|
| 2016 |
Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, et al. Adaptive Randomization of Neratinib in Early Breast Cancer. The New England Journal of Medicine. 375: 11-22. PMID 27406346 DOI: 10.1056/Nejmoa1513750 |
0.52 |
|
| 2016 |
Bertrand KA, Baer HJ, Orav EJ, Klifa C, Kumar A, Hylton NM, LeBlanc ES, Snetselaar LG, Van Horn L, Dorgan JF. Early life body fatness, serum antimüllerian hormone and breast density in young adult women. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27197299 DOI: 10.1158/1055-9965.Epi-16-0185 |
0.478 |
|
| 2016 |
Keenan KE, Peskin AP, Wilmes LJ, Aliu SO, Jones EF, Li W, Kornak J, Newitt DC, Hylton NM. Variability and bias assessment in breast ADC measurement across multiple systems. Journal of Magnetic Resonance Imaging : Jmri. PMID 27008431 DOI: 10.1002/Jmri.25237 |
0.82 |
|
| 2016 |
Keenan KE, Wilmes LJ, Aliu SO, Newitt DC, Jones EF, Boss MA, Stupic KF, Russek SE, Hylton NM. Design of a breast phantom for quantitative MRI. Journal of Magnetic Resonance Imaging : Jmri. PMID 26949897 DOI: 10.1002/Jmri.25214 |
0.825 |
|
| 2016 |
Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. Plos One. 11: e0142047. PMID 26886725 DOI: 10.1371/Journal.Pone.0142047 |
0.577 |
|
| 2016 |
Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, et al. Quantitative Imaging in Cancer Clinical Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 284-90. PMID 26773162 DOI: 10.1158/1078-0432.Ccr-14-3336 |
0.391 |
|
| 2016 |
Greenwood HI, Arasu VA, Deshphande VS, Wisner DJ, Laub GA, Hylton NM, Joe BN. Achieving Consistent, Homogeneous, Dark Fat Suppression on BilateralBreast MRI at 3.0 Tesla in the Clinical Setting Omics Journal of Radiology. 2016. DOI: 10.4172/2167-7964.1000230 |
0.504 |
|
| 2016 |
Albain K, Leyland-Jones B, Symmans F, Paoloni M, Veer Lv', DeMichele A, Buxton M, Hylton N, Yee D, Clennell JL, Yau C, Sanil A, Investigators IT, Berry D, Esserman L. Abstract P1-14-03: The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P1-14-03 |
0.506 |
|
| 2016 |
Buxton M, DeMichele AM, Chia S, Veer Lv, Chien J, Wallace A, Kaplan H, Lang J, Yee D, Isaacs C, Moulder S, Albain K, Boughey J, Kemmer K, Haley B, ... ... Hylton N, et al. Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct106 |
0.476 |
|
| 2016 |
DeMichele AM, Moulder S, Buxton M, Yee D, Wallace A, Chien J, Isaacs C, Albain K, Boughey J, Kemmer K, Haley B, Lang J, Kaplan H, Minton S, Forero A, ... ... Hylton N, et al. Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct042 |
0.453 |
|
| 2015 |
Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD, et al. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 150013. PMID 26624971 DOI: 10.1148/Radiol.2015150013 |
0.559 |
|
| 2015 |
Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World Journal of Clinical Cases. 3: 607-13. PMID 26244152 DOI: 10.12998/Wjcc.V3.I7.607 |
0.575 |
|
| 2015 |
Bertrand KA, Baer HJ, Orav EJ, Klifa C, Shepherd JA, Van Horn L, Snetselaar L, Stevens VJ, Hylton NM, Dorgan JF. Body fatness during childhood and adolescence and breast density in young women: a prospective analysis. Breast Cancer Research : Bcr. 17: 95. PMID 26174168 DOI: 10.1186/S13058-015-0601-4 |
0.413 |
|
| 2015 |
Jung S, Egleston BL, Chandler DW, Van Horn L, Hylton NM, Klifa CC, Lasser NL, LeBlanc ES, Paris K, Shepherd JA, Snetselaar LG, Stanczyk FZ, Stevens VJ, Dorgan JF. Adolescent endogenous sex hormones and breast density in early adulthood. Breast Cancer Research : Bcr. 17: 77. PMID 26041651 DOI: 10.1158/1055-9965.Epi-15-0108 |
0.468 |
|
| 2015 |
Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD. Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy. Plos One. 10: e0122151. PMID 25816249 DOI: 10.1371/Journal.Pone.0122151 |
0.559 |
|
| 2015 |
Karp NL, Price ER, Wisner DJ, Chang CB, Hylton NM, Joe BN. Extra-mammary findings on breast MRI: a pictorial review. Clinical Imaging. 39: 547-552. PMID 25772531 DOI: 10.1016/J.Clinimag.2015.01.019 |
0.574 |
|
| 2015 |
Newitt DC, Tan ET, Wilmes LJ, Chenevert TL, Kornak J, Marinelli L, Hylton N. Gradient nonlinearity correction to improve apparent diffusion coefficient accuracy and standardization in the american college of radiology imaging network 6698 breast cancer trial. Journal of Magnetic Resonance Imaging : Jmri. PMID 25758543 DOI: 10.1002/Jmri.24883 |
0.519 |
|
| 2015 |
DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, ... ... Hylton NM, et al. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2911-5. PMID 25712686 DOI: 10.1158/1078-0432.Ccr-14-1760 |
0.492 |
|
| 2015 |
Hollowell L, Price E, Arasu V, Wisner D, Hylton N, Joe B. Lesion morphology on breast MRI affects targeted ultrasound correlation rate. European Radiology. 25: 1279-1284. PMID 25500714 DOI: 10.1007/S00330-014-3517-Y |
0.44 |
|
| 2015 |
Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter P, Mehta R, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman P, Yodh AG, Chung S, ... ... Hylton N, et al. Abstract S4-04: Predicting pre-surgical neoadjuvant chemotherapy response in breast cancer using diffuse optical spectroscopic imaging (DOSI): Results from the ACRIN 6691 study Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S4-04 |
0.558 |
|
| 2015 |
Yau C, Wolf D, Sanil A, Veer Lv', Petricoin EF, Buxton M, Gray J, DeMichele A, Hogarth M, Hylton N, Perlmutter J, Paoloni M, Symmans F, Yee D, Berry D, et al. Abstract P3-06-37: I-SPY 2 qualifying biomarker evaluation (QBE): The challenge and opportunity for interrogating predicted pathways in an adaptive design biomarker rich trial Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-37 |
0.385 |
|
| 2015 |
Yau C, Wolf DM, Sanil A, Chien J, Wallace A, Boughey J, Yee D, Tripathy D, DeMichele A, Nanda R, Chiu S, Isaacs C, Albain K, Kaplan H, Moulder S, ... ... Hylton N, et al. Abstract P3-06-29: MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-29 |
0.434 |
|
| 2015 |
Wolf DM, Yau C, Sanil A, Chien J, Wallace A, DeMichele A, Kaplan H, Yee D, Isaacs C, Albain K, Viscuzi R, Boughey J, Moulder S, Chui S, Khan Q, ... ... Hylton N, et al. Abstract P3-06-25: MammaPrint High1/High2 risk class as a biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-25 |
0.403 |
|
| 2015 |
Fournier MV, Derr A, Margulis A, Reid K, Brumbaugh S, Anderson R, Symmans WF, Esserman L, Hylton N. Abstract P3-06-19: Gene expression profiles accompanying phenotypic changes during non-malignant breast epithelial cells acini formation to explain MRI phenotypes Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-19 |
0.521 |
|
| 2015 |
Wulfkuhle JD, Yau C, Wolf DM, Gallagher RI, Sanil A, Brown-Swigart L, Flynn S, Hirst G, Investigators IT, Buxton M, DeMichele A, Hylton N, Symmans WF, Veer Lv, Yee D, et al. Abstract P3-06-15: Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 trial Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-15 |
0.365 |
|
| 2015 |
Wolf DM, Yau C, Sanil A, Daemen A, Heiser L, Gray J, Brown-Swigart L, Flynn S, Hirst G, Investigators IT, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, et al. Abstract P3-06-05: Evaluation of anin vitroderived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL: Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-05 |
0.443 |
|
| 2015 |
Li W, Lo W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Hylton NM. Abstract P1-01-09: Optimization of magnetic resonance imaging predictive performance by breast cancer subtypes for predicting response to neoadjuvant chemotherapy Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-01-09 |
0.51 |
|
| 2014 |
Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1464-83. PMID 24807204 DOI: 10.1158/1055-9965.Epi-13-1170 |
0.534 |
|
| 2014 |
Aliu SO, Jones EF, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM. Repeatability of quantitative MRI measurements in normal breast tissue. Translational Oncology. 7: 130-7. PMID 24772216 DOI: 10.1593/Tlo.13841 |
0.826 |
|
| 2014 |
Boes JL, Hoff BA, Hylton N, Pickles MD, Turnbull LW, Schott AF, Rehemtulla A, Chamberlain R, Lemasson B, Chenevert TL, Galbán CJ, Meyer CR, Ross BD. Image registration for quantitative parametric response mapping of cancer treatment response. Translational Oncology. 7: 101-10. PMID 24772213 DOI: 10.1593/Tlo.14121 |
0.566 |
|
| 2014 |
Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform. Translational Oncology. 7: 94-100. PMID 24772212 DOI: 10.1593/Tlo.13877 |
0.815 |
|
| 2014 |
Chenevert TL, Malyarenko DI, Newitt D, Li X, Jayatilake M, Tudorica A, Fedorov A, Kikinis R, Liu TT, Muzi M, Oborski MJ, Laymon CM, Li X, Thomas Y, Jayashree KC, ... ... Hylton N, et al. Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling. Translational Oncology. 7: 65-71. PMID 24772209 DOI: 10.1593/Tlo.13811 |
0.363 |
|
| 2014 |
McLaughlin RL, Newitt DC, Wilmes LJ, Jones EF, Wisner DJ, Kornak J, Proctor E, Joe BN, Hylton NM. High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging. Journal of Magnetic Resonance Imaging : Jmri. 39: 1308-13. PMID 24719242 DOI: 10.1002/Jmri.24283 |
0.513 |
|
| 2014 |
Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. Journal of Magnetic Resonance Imaging : Jmri. 40: 476-82. PMID 24347097 DOI: 10.1002/Jmri.24351 |
0.582 |
|
| 2014 |
Wisner DJ, Rogers N, Deshpande VS, Newitt DN, Laub GA, Porter DA, Kornak J, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3T. Journal of Magnetic Resonance Imaging : Jmri. 40: 674-81. PMID 24214467 DOI: 10.1002/Jmri.24416 |
0.509 |
|
| 2014 |
Aliu SO, Jones EF, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM. Repeatability of quantitative MRI measurements in normal breast tissue Translational Oncology. 7: 130-137. DOI: 10.1593/tlo.13841 |
0.821 |
|
| 2014 |
Buxton MB, Natsuhara K, DeMichele A, Perlmutter J, Hylton NM, Yee D, Veer Lv, Symmans WF, Hogarth M, Lyandres J, Davis SE, Flynn S, Paoloni M, Berry DA, Esserman L. Transforming the clinical trial process: The I-SPY 2 trial as a model for improving the efficiency of clinical trials and accelerating the drug-screening process. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps2633 |
0.374 |
|
| 2014 |
Park JW, Liu MC, Yee D, DeMichele A, Veer Lv', Hylton N, Symmans F, Buxton MB, Chien AJ, Wallace A, Melisko M, Schwab R, Boughey J, Tripathy D, Kaplan H, et al. Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct227 |
0.474 |
|
| 2014 |
Glas A, Peeters J, Yau C, Wolf D, Sanil A, Li Y, Severson T, Linn S, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, et al. 532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial European Journal of Cancer. 50: 173. DOI: 10.1016/S0959-8049(14)70658-6 |
0.449 |
|
| 2013 |
Wang J, Azziz A, Fan B, Malkov S, Klifa C, Newitt D, Yitta S, Hylton N, Kerlikowske K, Shepherd JA. Agreement of mammographic measures of volumetric breast density to MRI. Plos One. 8: e81653. PMID 24324712 DOI: 10.1371/Journal.Pone.0081653 |
0.569 |
|
| 2013 |
Wisner DJ, Hwang ES, Chang CB, Tso HH, Joe BN, Lessing JN, Lu Y, Hylton NM. Features of occult invasion in biopsy-proven DCIS at breast MRI. The Breast Journal. 19: 650-8. PMID 24165314 DOI: 10.1111/Tbj.12201 |
0.47 |
|
| 2013 |
Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO, Van Horn L, Snetselaar LG, Stevens VJ, Robson AM, Lasser NL, Hylton NM. Menstrual and reproductive characteristics and breast density in young women. Cancer Causes & Control : Ccc. 24: 1973-83. PMID 23933948 DOI: 10.1007/S10552-013-0273-2 |
0.496 |
|
| 2013 |
Ojeda-Fournier H, de Guzman J, Hylton N. Breast magnetic resonance imaging for monitoring response to therapy. Magnetic Resonance Imaging Clinics of North America. 21: 533-46. PMID 23928243 DOI: 10.1016/J.Mric.2013.04.005 |
0.595 |
|
| 2013 |
Bolouri MS, Elias SG, Wisner DJ, Behr SC, Hawkins RA, Suzuki SA, Banfield KS, Joe BN, Hylton NM. Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging. Radiology. 269: 354-61. PMID 23878283 DOI: 10.1148/Radiol.13130058 |
0.512 |
|
| 2013 |
Mukhtar RA, Yau C, Rosen M, Tandon VJ, Investigators A, Hylton N, Esserman LJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Annals of Surgical Oncology. 20: 3823-3830. PMID 23780381 DOI: 10.1245/S10434-013-3038-Y |
0.46 |
|
| 2013 |
Lehman CD, Blume JD, DeMartini WB, Hylton NM, Herman B, Schnall MD. Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers. Ajr. American Journal of Roentgenology. 200: W683-9. PMID 23701102 DOI: 10.2214/Ajr.11.8394 |
0.522 |
|
| 2013 |
Yitta S, Joe BN, Wisner DJ, Price ER, Hylton NM. Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T. Ajr. American Journal of Roentgenology. 200: W673-82. PMID 23701101 DOI: 10.2214/Ajr.12.10013 |
0.562 |
|
| 2013 |
Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM. MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. Plos One. 8: e61969. PMID 23667451 DOI: 10.1371/Journal.Pone.0061969 |
0.508 |
|
| 2013 |
Mahoney ME, Gordon EJ, Rao JY, Jin Y, Hylton N, Love SM. Intraductal therapy of ductal carcinoma in situ: a presurgery study. Clinical Breast Cancer. 13: 280-6. PMID 23664819 DOI: 10.1016/J.Clbc.2013.02.002 |
0.386 |
|
| 2013 |
Wilmes LJ, McLaughlin RL, Newitt DC, Singer L, Sinha SP, Proctor E, Wisner DJ, Saritas EU, Kornak J, Shankaranarayanan A, Banerjee S, Jones EF, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response. Academic Radiology. 20: 581-9. PMID 23570936 DOI: 10.1016/J.Acra.2013.01.009 |
0.497 |
|
| 2013 |
De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 119: 1776-83. PMID 23436342 DOI: 10.1002/Cncr.27995 |
0.546 |
|
| 2013 |
Hylton N. MR imaging for the prediction of breast cancer response to neoadjuvant chemotherapy. Radiology. 266: 367. PMID 23390630 DOI: 10.1148/Radiol.12124051 |
0.425 |
|
| 2013 |
Rugo H, Olopade O, DeMichele A, Veer Lv', Buxton M, Hylton N, Yee D, Chien A, Wallace A, PI's IS, Lyandres J, Davis S, Sanil A, Berry D, Esserman L. Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-S5-02 |
0.48 |
|
| 2013 |
McGuire K, Santos JDL, Cantor A, Forero A, Golshan M, Meric-Bernstam F, Horton J, Amos K, Hudis C, Hylton N, Meszoely I, Nanda R, Hwang S. Abstract P1-01-04: Nodal patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy: Results of a secondary analysis of TBCRC 017 Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P1-01-04 |
0.37 |
|
| 2013 |
Hylton N. Abstract ES08-3: MR imaging for predicting response to neoadjuvant treatment Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Es08-3 |
0.625 |
|
| 2012 |
Dorgan JF, Klifa C, Shepherd JA, Egleston BL, Kwiterovich PO, Himes JH, Gabriel K, Horn L, Snetselaar LG, Stevens VJ, Barton BA, Robson AM, Lasser NL, Deshmukh S, Hylton NM. Height, adiposity and body fat distribution and breast density in young women. Breast Cancer Research : Bcr. 14: R107. PMID 22800711 DOI: 10.1186/Bcr3228 |
0.494 |
|
| 2012 |
Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M. A common language in neoadjuvant breast cancer clinical trials: Proposals for standard definitions and endpoints The Lancet Oncology. 13: e240-e248. PMID 22652232 DOI: 10.1016/S1470-2045(11)70378-3 |
0.511 |
|
| 2012 |
Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, ... ... Hylton N, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3242-9. PMID 22649152 DOI: 10.1200/Jco.2011.39.2779 |
0.513 |
|
| 2012 |
Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 263: 663-72. PMID 22623692 DOI: 10.1148/Radiol.12110748 |
0.565 |
|
| 2012 |
Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, ... ... Hylton N, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment. 132: 1049-62. PMID 22198468 DOI: 10.1007/S10549-011-1895-2 |
0.493 |
|
| 2012 |
Singer L, Wilmes LJ, Saritas EU, Shankaranarayanan A, Proctor E, Wisner DJ, Chang B, Joe BN, Nishimura DG, Hylton NM. High-resolution diffusion-weighted magnetic resonance imaging in patients with locally advanced breast cancer. Academic Radiology. 19: 526-34. PMID 22197382 DOI: 10.1016/J.Acra.2011.11.003 |
0.562 |
|
| 2012 |
Elias SG, Wisner DJ, Chen Y, Behr SC, Griffin A, Esserman LJ, Veer LJv, Hylton NM. Abstract 4558: FDG-PET uptake in breast cancer molecular subtypes Cancer Research. 72: 4558-4558. DOI: 10.1158/1538-7445.Am2012-4558 |
0.474 |
|
| 2012 |
Wisner D, Rogers N, Deshpande V, Newitt D, Laub G, Porter D, Joe B, Hylton N. Abstract P4-01-10: High-resolution diffusion weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3 Tesla Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-01-10 |
0.477 |
|
| 2012 |
Jones E, Sinha S, Newitt D, Klifa C, Kornak J, Park C, Hylton N. Abstract P4-01-04: MRI enhancement in stromal tissue surrounding breast tumors: Association with RFS following neoadjuvant chemotherapy Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P4-01-04 |
0.549 |
|
| 2011 |
Tromberg BJ, Butler JA, Mankoff DA, Isakoff SJ, Hylton NM, Yodh AG, Boas D, Paulsen K, Pogue BW, Kaufman PA, Mehta RS, Carpenter PM, Cerussi A, Zhang Z, Hartfeil DM, et al. ACRIN 6691 monitoring and predicting breast cancer neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging (DOSI). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS249. PMID 28023578 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps249 |
0.491 |
|
| 2011 |
Partridge SC, Singer L, Sun R, Wilmes LJ, Klifa CS, Lehman CD, Hylton NM. Diffusion-weighted MRI: influence of intravoxel fat signal and breast density on breast tumor conspicuity and apparent diffusion coefficient measurements. Magnetic Resonance Imaging. 29: 1215-21. PMID 21920686 DOI: 10.1016/J.Mri.2011.07.024 |
0.572 |
|
| 2011 |
Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast (Edinburgh, Scotland). 20: 529-33. PMID 21843942 DOI: 10.1016/J.Breast.2011.06.001 |
0.336 |
|
| 2011 |
McLaughlin R, Hylton N. MRI in breast cancer therapy monitoring. Nmr in Biomedicine. 24: 712-720. PMID 21692116 DOI: 10.1002/Nbm.1739 |
0.55 |
|
| 2011 |
Liu S, Shah SJ, Wilmes LJ, Feiner J, Kodibagkar VD, Wendland MF, Mason RP, Hylton N, Hopf HW, Rollins MD. Quantitative tissue oxygen measurement in multiple organs using 19F MRI in a rat model. Magnetic Resonance in Medicine. 66: 1722-30. PMID 21688315 DOI: 10.1002/Mrm.22968 |
0.316 |
|
| 2011 |
Klifa C, Suzuki S, Aliu S, Singer L, Wilmes L, Newitt D, Joe B, Hylton N. Quantification of background enhancement in breast magnetic resonance imaging Journal of Magnetic Resonance Imaging. 33: 1229-1234. PMID 21509883 DOI: 10.1002/Jmri.22545 |
0.841 |
|
| 2011 |
Peng C, Chang CB, Tso HH, Flowers CI, Hylton NM, Joe BN. MRI appearance of tumor recurrence in myocutaneous flap reconstruction after mastectomy. Ajr. American Journal of Roentgenology. 196: W471-5. PMID 21427313 DOI: 10.2214/Ajr.10.5279 |
0.459 |
|
| 2011 |
Itakura K, Lessing J, Sakata T, Heinzerling A, Vriens E, Wisner D, Alvarado M, Esserman L, Ewing C, Hylton N, Hwang ES. The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ. Clinical Breast Cancer. 11: 33-8. PMID 21421520 DOI: 10.3816/Cbc.2011.N.006 |
0.398 |
|
| 2011 |
Arasu VA, Chen RC, Newitt DN, Chang CB, Tso H, Hylton NM, Joe BN. Can signal enhancement ratio (SER) reduce the number of recommended biopsies without affecting cancer yield in occult MRI-detected lesions? Academic Radiology. 18: 716-21. PMID 21420333 DOI: 10.1016/J.Acra.2011.02.008 |
0.49 |
|
| 2011 |
Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokayasu T, Olshen AB, Spellman P, Gray JW, Hylton N, Park CC. Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI. Integrative Biology : Quantitative Biosciences From Nano to Macro. 3: 490-6. PMID 21416100 DOI: 10.1039/C0Ib00089B |
0.587 |
|
| 2011 |
Wolf D, Lenburg M, Yau C, Boudreau A, Esserman L, Hylton N, Veer LV'. Abstract LB-311: Combinatorial logic over breast cancer control modules predicts survival and chemotherapy response of ISPY1 breast cancer patients (CALGB 150007/150012; ACRIN 6657) Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-311 |
0.431 |
|
| 2011 |
Mukhtar R, Hylton N, Rosen M. PD02-05: MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd02-05 |
0.528 |
|
| 2011 |
McLaughlin R, Newitt D, Wilmes L, Sinha S, Wisner D, Hylton N. P2-09-12: High Resolution Diffusion MRI Characterizes Tumor Stromal Boundaries. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-09-12 |
0.422 |
|
| 2011 |
Wilmes L, McLaughlin R, Sinha S, Singer L, Proctor E, Wisner D, Newitt D, Shankaranarayanan A, Joe B, Hylton N. P2-08-06: Improved Spatial Resolution Diffusion-Weighted Imaging for Characterizing Tumors and Treatment Response in Patients with Invasive Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-08-06 |
0.524 |
|
| 2011 |
Wolf D, Yau C, Benz S, Vaske C, Stuart J, Roy R, Olshen A, Boudreau A, Haussler D, Gray J, Spellman P, Davis S, Hylton N, Veer LV, Esserman L. P1-06-09: Patient-Specific Integrative Pathway Analysis Using PARADIGM Identifies Key Activities in I-SPY 1 Breast Cancer Patients (CALGB 150007/150012; ACRIN 6657). Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-06-09 |
0.426 |
|
| 2011 |
Tromberg B, L'Heureux D, Mankoff D, Zhang Z, Cerussi A, Mehta R, Carpenter P, Butler J, Hylton N, Kaufman P, Pogue B, Paulsen K, Yodh A, Boas D, Isakoff S. OT2-05-02: ACRIN 6691 Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI). Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot2-05-02 |
0.523 |
|
| 2011 |
Hylton N, Partridge S, Rosen M, Kim E, L'Heureux D, Esseman L. OT2-03-06: ACRIN 6698 MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: A Sub-Study of the I-SPY 2 TRIAL (Investigation of Serial Studies To Predict Your Therapeutic Response with Imaging And moLecular Analysis). Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot2-03-06 |
0.591 |
|
| 2011 |
Nabavizadeh N, Klifa C, Newitt D, Lu Y, Chen YY, Hsu H, Fisher C, Tokuyasu T, Olshen AB, Spellman P, Gray JW, Hylton N, Park CC. Topographic enhancement mapping of the cancer-associated breast stroma using breast MRI (Integrative Biology (2011) 3 (910-921) DOI:10.1039/C1IB00043H) Integrative Biology. 3: 1233. DOI: 10.1039/C1Ib90045E |
0.539 |
|
| 2010 |
Dorgan JF, Liu L, Klifa C, Hylton N, Shepherd JA, Stanczyk FZ, Snetselaar LG, Van Horn L, Stevens VJ, Robson A, Kwiterovich PO, Lasser NL, Himes JH, Pettee Gabriel K, Kriska A, et al. Adolescent diet and subsequent serum hormones, breast density, and bone mineral density in young women: results of the Dietary Intervention Study in Children follow-up study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 1545-56. PMID 20501774 DOI: 10.1158/1055-9965.Epi-09-1259 |
0.39 |
|
| 2010 |
Le-Petross HC, Hylton N. Role of breast MR imaging in neoadjuvant chemotherapy. Magnetic Resonance Imaging Clinics of North America. 18: 249-258. PMID 20494310 DOI: 10.1016/J.Mric.2010.02.008 |
0.515 |
|
| 2010 |
Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Research and Treatment. 119: 137-44. PMID 19728082 DOI: 10.1007/S10549-009-0507-X |
0.543 |
|
| 2010 |
Klifa C, Carballido-Gamio J, Wilmes L, Laprie A, Shepherd J, Gibbs J, Fan B, Noworolski S, Hylton N. Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort. Magnetic Resonance Imaging. 28: 8-15. PMID 19631485 DOI: 10.1016/J.Mri.2009.05.040 |
0.573 |
|
| 2009 |
Pradhan SM, Carey L, Edmiston S, Hylton N, Parrish E, Moore D, Conway K. P53 mutation and differential response to neoadjuvant chemotherapy in women with locally advanced breast cancer: Results from the I-SPY trial (CALGB 150007/1500012 and ACRIN 6657). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11099. PMID 27963126 DOI: 10.1200/Jco.2009.27.15_Suppl.11099 |
0.454 |
|
| 2009 |
Nabavizadeh N, Klifa C, Newitt D, Lu Y, Hattangadi J, Fisher C, Hylton N, Park C. MR quantification of abnormal stromal enhancement in the periphery of invasive breast tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 636. PMID 27961446 DOI: 10.1200/Jco.2009.27.15_Suppl.636 |
0.578 |
|
| 2009 |
Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, et al. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5569-75. PMID 19706807 DOI: 10.1158/1078-0432.Ccr-09-0522 |
0.362 |
|
| 2009 |
Hylton NM. Can diffuse optical spectroscopic tomography be used to characterize breast lesions and their response to treatment? Radiology. 252: 330-1. PMID 19703876 DOI: 10.1148/Radiol.2522090830 |
0.407 |
|
| 2009 |
Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology and Therapeutics. 86: 97-100. PMID 19440188 DOI: 10.1038/Clpt.2009.68 |
0.469 |
|
| 2009 |
Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. Journal of Magnetic Resonance Imaging : Jmri. 29: 1071-9. PMID 19388114 DOI: 10.1002/Jmri.21737 |
0.821 |
|
| 2009 |
Esserman LJ, Perou C, Cheang M, DeMichele A, Carey L, van 't Veer LJ, Gray J, Petricoin E, Conway K, Hylton N, Berry D. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) Journal of Clinical Oncology. 27: LBA515-LBA515. DOI: 10.1200/Jco.2009.27.18_Suppl.Lba515 |
0.45 |
|
| 2009 |
Newitt D, Gibbs J, Partridge S, Li K, Lobo E, Esserman L, Hylton N. Comparison of MRI tumor volumetric and diameter measurements for predicting recurrence free survival in breast cancer patients undergoing preoperative chemotherapy. Cancer Research. 69: 6053. DOI: 10.1158/0008-5472.Sabcs-6053 |
0.542 |
|
| 2009 |
Hylton N, Blume J, Bernreuter W, Pisano E, Rosen M, Morris E, Weatherall P, Lehman C, Polin S, Newstead G, Marques H, Schnall, Esserman L, Team AT, Investigators IT. Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657. Cancer Research. 69: 6043. DOI: 10.1158/0008-5472.Sabcs-6043 |
0.564 |
|
| 2009 |
Garwood E, Kumar A, Baehner F, Garber J, Troyan S, Olopade O, Moore D, Au A, Flowers C, Campbell M, Hylton N, Esserman L, Rush-Port E. Fluvastatin has biologic effects on stage 0 and 1 breast cancer. Cancer Research. 69: 4122. DOI: 10.1158/0008-5472.Sabcs-4122 |
0.499 |
|
| 2009 |
Klifa C, Gibbs J, Hattangadi J, Hylton N. Quantitative MRI assessment of uninvolved breast tissue in patients with locally-advanced breast cancer undergoing neoadjuvant chemotherapy. Cancer Research. 69: 4016. DOI: 10.1158/0008-5472.Sabcs-4016 |
0.584 |
|
| 2009 |
Rosen M, Marques H, Herman B, Mies C, DiMichele A, Partridge S, Lehman C, Gatsonis C, Esserman L, Hylton N. Magnetic Resonance Imaging Morphologic Features of Advanced Breast Cancer Predict Surgical and Pathologic Outcomes after Neoadjuvant Chemotherapy. Cancer Research. 69: 4016-4016. DOI: 10.1158/0008-5472.Sabcs-09-4016 |
0.569 |
|
| 2009 |
Veer Lv', Das D, DeMichele A, Lenburg M, Singh B, Gray J, Berry D, Hylton N, Esserman L, Investigators I. Neoadjuvant Response in the Context of a Biologically Defined Low or High Risk Tumor Has a Different Clinical Consequence, the I-SPY Trial (CALGB 150007/150012, ACRIN 6657). Cancer Research. 69: 2003-2003. DOI: 10.1158/0008-5472.Sabcs-09-2003 |
0.407 |
|
| 2009 |
Nabavizadeh N, Klifa C, Chen Y, Newitt D, Lu Y, Hattangadi J, Fisher C, Hylton N, Park C. MRI and Histologic Quantification of Neoangiogenesis in Normal Appearing Breast Beyond the Tumor Margin: Implications for Local Treatment International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.441 |
0.545 |
|
| 2008 |
Chien AJ, Illi JA, Ko AH, Dubey S, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I dose escalation study of a 2 day lapatinib chemosensitization pulse preceding weekly intravenous nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in patients with advanced cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3595. PMID 27949373 DOI: 10.1200/Jco.2008.26.15_Suppl.3595 |
0.328 |
|
| 2008 |
Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology. 248: 79-87. PMID 18566170 DOI: 10.1148/Radiol.2481070846 |
0.529 |
|
| 2008 |
Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J, Hylton N. Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy. Ajr. American Journal of Roentgenology. 190: 1630-6. PMID 18492917 DOI: 10.2214/Ajr.07.2533 |
0.608 |
|
| 2008 |
Gomez RE, Hylton N, Madhavan S, Leung E, Broadwater G, Herman B, Esserman L. 153. Breast Tumor Patterns on Pretreatment MRI Predict Breast Conservation Therapy Eligibility Journal of Surgical Research. 144: 245. DOI: 10.1016/J.Jss.2007.12.174 |
0.555 |
|
| 2007 |
Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. Journal of Magnetic Resonance Imaging : Jmri. 26: 1618-25. PMID 17968965 DOI: 10.1002/Jmri.21196 |
0.773 |
|
| 2007 |
Li KL, Henry RG, Wilmes LJ, Gibbs J, Zhu X, Lu Y, Hylton NM. Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging. Magnetic Resonance in Medicine. 58: 572-81. PMID 17685424 DOI: 10.1002/Mrm.21361 |
0.504 |
|
| 2007 |
Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magnetic Resonance Imaging. 25: 319-27. PMID 17371720 DOI: 10.1016/J.Mri.2006.09.041 |
0.517 |
|
| 2007 |
Klifa CS, Shimakawa A, Siraj Z, Gibbs JE, Wilmes LJ, Partridge SC, Proctor E, Hylton NM. Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging. Journal of Magnetic Resonance Imaging : Jmri. 25: 82-8. PMID 17173311 DOI: 10.1002/Jmri.20775 |
0.377 |
|
| 2007 |
Klifa CS, Hattangadi J, Watkins M, Li A, Sakata T, Tromberg B, Hylton N, Park C. Combination of magnetic resonance imaging and diffuse optical spectroscopy to predict radiation response in the breast: an exploratory pilot study Proceedings of Spie. 6431. DOI: 10.1117/12.705675 |
0.502 |
|
| 2007 |
Hattangadi J, Klifa C, Hwang J, Watkins M, Sakata T, Tromberg B, Hylton N, Park C. Non-Invasive Imaging Techniques Quantitate Radiation Induced Vascular Changes in the Breast International Journal of Radiation Oncology*Biology*Physics. 69: S233. DOI: 10.1016/J.Ijrobp.2007.07.1222 |
0.458 |
|
| 2006 |
Hylton N. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magnetic Resonance Imaging Clinics of North America. 14: 383-389. PMID 17098179 DOI: 10.1016/J.Mric.2006.09.001 |
0.59 |
|
| 2006 |
Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4603-10. PMID 17008702 DOI: 10.1200/Jco.2005.04.5518 |
0.465 |
|
| 2006 |
Kumar AS, Chen DF, Au A, Chen YY, Leung J, Garwood ER, Gibbs J, Hylton N, Esserman LJ. Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ. American Journal of Surgery. 192: 520-4. PMID 16978965 DOI: 10.1016/J.Amjsurg.2006.07.003 |
0.468 |
|
| 2006 |
Hylton N. Dynamic Contrast-Enhanced Magnetic Resonance Imaging As an Imaging Biomarker Journal of Clinical Oncology. 24: 3293-3298. PMID 16829653 DOI: 10.1200/Jco.2006.06.8080 |
0.468 |
|
| 2006 |
Schnall MD, Blume J, Bluemke DA, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Thickman D, Stelling CB, Weatherall PT, et al. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology. 238: 42-53. PMID 16373758 DOI: 10.1148/Radiol.2381042117 |
0.51 |
|
| 2006 |
Klifa C, Li A, Hattangadi J, Shah N, Gibbs J, DeMicco E, Watkins M, Proctor E, Cerussi A, Tromberg B, Hylton N. Study of Breast Tissue Composition Using Magnetic Resonance Imaging and Diffuse Optical Spectroscopy Biosilico. DOI: 10.1364/Bio.2006.Sg4 |
0.552 |
|
| 2006 |
Park C, Hattangadi J, Rembert J, Hwang J, Klifa C, Lu Y, Hylton N. Abstract2048: Breast Magnetic Resonance Imaging (MRI) Enhancement Beyond the Tumor Margin: Is There An Association With Treatment Response? International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.451 |
0.552 |
|
| 2005 |
Shah N, Gibbs J, Wolverton D, Cerussi A, Hylton N, Tromberg BJ. Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neoadjuvant chemotherapy: a case study. Journal of Biomedical Optics. 10: 051503. PMID 16292947 DOI: 10.1117/1.2070147 |
0.55 |
|
| 2005 |
Schnall MD, Blume J, Bluemke DA, Deangelis GA, Debruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, Lehman C, et al. MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. Journal of Surgical Oncology. 92: 32-8. PMID 16180227 DOI: 10.1002/Jso.20381 |
0.56 |
|
| 2005 |
Lehman CD, Blume JD, Thickman D, Bluemke DA, Pisano E, Kuhl C, Julian TB, Hylton N, Weatherall P, O'loughlin M, Schnitt SJ, Gatsonis C, Schnall MD. Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial. Journal of Surgical Oncology. 92: 9-15; discussion 15-. PMID 16180217 DOI: 10.1002/Jso.20350 |
0.569 |
|
| 2005 |
Li KL, Wilmes LJ, Henry RG, Pallavicini MG, Park JW, Hu-Lowe DD, McShane TM, Shalinsky DR, Fu YJ, Brasch RC, Hylton NM. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. Journal of Magnetic Resonance Imaging : Jmri. 22: 511-9. PMID 16161072 DOI: 10.1002/Jmri.20387 |
0.455 |
|
| 2005 |
Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. Ajr. American Journal of Roentgenology. 184: 1774-81. PMID 15908529 DOI: 10.2214/Ajr.184.6.01841774 |
0.499 |
|
| 2005 |
Frei KA, Bonel HM, Pelte MF, Hylton NM, Kinkel K. Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation. Investigative Radiology. 40: 363-7. PMID 15905723 DOI: 10.1097/01.Rli.0000163742.40401.4E |
0.579 |
|
| 2005 |
Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O'Loughlin M, Harms S, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 103: 1898-905. PMID 15800894 DOI: 10.1002/Cncr.20971 |
0.505 |
|
| 2005 |
Hylton N. Magnetic Resonance Imaging of the Breast: Opportunities to Improve Breast Cancer Management Journal of Clinical Oncology. 23: 1678-1684. PMID 15755976 DOI: 10.1200/Jco.2005.12.002 |
0.599 |
|
| 2004 |
Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, Heywang-Köbrunner SH, Hylton N, Kuhl CK, Lehman C, Pisano ED, Causer P, Schnitt SJ, Smazal SF, Stelling CB, et al. Magnetic resonance imaging of the breast prior to biopsy. Jama. 292: 2735-42. PMID 15585733 DOI: 10.1001/Jama.292.22.2735 |
0.575 |
|
| 2004 |
Shah N, Cerussi A, Tromberg B, Wolverton D, Klifa C, Gibbs J, Hylton N. Diffuse Optical Spectroscopy and Magnetic Resonance Imaging of Breast Tissue Biosilico. DOI: 10.1364/Bio.2004.Wa4 |
0.516 |
|
| 2004 |
Esserman L, Hylton N. Seminars in Oncology: The Emerging Role of MRI in Neoadjuvant Therapy Seminars in Breast Disease. 7: 75-78. DOI: 10.1053/J.Sembd.2005.02.001 |
0.565 |
|
| 2003 |
Hylton NM. Evaluation of gadobenate dimeglumine for contrast-enhanced MRI of the breast. Ajr. American Journal of Roentgenology. 181: 677-8. PMID 12933458 DOI: 10.2214/Ajr.181.3.1810677 |
0.562 |
|
| 2003 |
Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Annals of Surgical Oncology. 10: 381-8. PMID 12734086 DOI: 10.1245/Aso.2003.03.085 |
0.532 |
|
| 2003 |
Yu E, Gibbs J, Au A, Chew K, Hylton N, Esserman L, Hwang S, Ewing C, Rugo H, Park J, Tripathy D. Mri Phenotypes Predict Response And Recurrence In Locally Advanced Breast Cancer Treated With Neoadjuvant Chemotherapy. Journal of Investigative Medicine. 51: 340-340. DOI: 10.1136/Jim-51-06-29 |
0.53 |
|
| 2002 |
Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Ajr. American Journal of Roentgenology. 179: 1193-9. PMID 12388497 DOI: 10.2214/Ajr.179.5.1791193 |
0.51 |
|
| 2002 |
Esserman L, Wolverton D, Hylton N. Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocrine-Related Cancer. 9: 141-153. PMID 12121836 DOI: 10.1677/Erc.0.0090141 |
0.554 |
|
| 2001 |
Partridge SC, McKinnon GC, Henry RG, Hylton NM. Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI Journal of Magnetic Resonance Imaging. 14: 433-438. PMID 11599068 DOI: 10.1002/Jmri.1204 |
0.558 |
|
| 2001 |
Hylton NM. Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging Magnetic Resonance Imaging Clinics of North America. 9: 321-331. PMID 11493422 |
0.457 |
|
| 2001 |
Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Annals of Surgical Oncology. 8: 549-59. PMID 11456056 DOI: 10.1007/S10434-001-0549-8 |
0.518 |
|
| 2001 |
Ikeda DM, Hylton NM, Kinkel K, Hochman MG, Kuhl CK, Kaiser WA, Weinreb JC, Smazal SF, Degani H, Viehweg P, Barclay J, Schnall MD. Development, standardization, and testing of a lexicon for reporting contrast-enhanced breast magnetic resonance imaging studies. Journal of Magnetic Resonance Imaging : Jmri. 13: 889-95. PMID 11382949 DOI: 10.1002/Jmri.1127 |
0.564 |
|
| 2001 |
Kinkel K, Hylton NM. Challenges to interpretation of breast MRI Journal of Magnetic Resonance Imaging. 13: 821-829. PMID 11382939 DOI: 10.1002/Jmri.1117 |
0.561 |
|
| 2000 |
Esserman LJ, Wolverton D, Hylton N. Integration of breast imaging into cancer management. Current Oncology Reports. 2: 572-581. PMID 11122895 DOI: 10.1007/S11912-000-0112-Y |
0.488 |
|
| 2000 |
Frei KA, Kinkel K, Bonel HM, Lu Y, Esserman LJ, Hylton NM. MR imaging of the breast in patients with positive margins after lumpectomy: Influence of the time interval between lumpectomy and MR imaging American Journal of Roentgenology. 175: 1577-1584. PMID 11090379 DOI: 10.2214/Ajr.175.6.1751577 |
0.539 |
|
| 2000 |
Hylton NM. Suspension of breast-feeding following gadopentetate dimeglumine administration Radiology. 216: 325-326. PMID 10924547 DOI: 10.1148/Radiology.216.2.R00Au55325 |
0.503 |
|
| 2000 |
Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. Ajr. American Journal of Roentgenology. 175: 35-43. PMID 10882243 DOI: 10.2214/Ajr.175.1.1750035 |
0.462 |
|
| 1999 |
Esserman L, Hylton N, George T, Weidner N. Contrast‐Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma Breast Journal. 5: 13-21. PMID 11348250 DOI: 10.1046/J.1524-4741.1999.005001013.X |
0.522 |
|
| 1999 |
Hylton N. Dedicated Breast MRI Systems Working Group report. Journal of Magnetic Resonance Imaging. 10: 1006-1009. PMID 10581519 DOI: 10.1002/(Sici)1522-2586(199912)10:6<1006::Aid-Jmri18>3.0.Co;2-5 |
0.48 |
|
| 1999 |
Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 110-9. PMID 10458224 DOI: 10.1200/Jco.1999.17.1.110 |
0.57 |
|
| 1998 |
Hylton NM, Kinkel K. Technical aspects of breast magnetic resonance imaging Topics in Magnetic Resonance Imaging. 9: 3-16. PMID 9617899 DOI: 10.1097/00002142-199802000-00002 |
0.536 |
|
| 1994 |
Hylton NM, Frankel SD. Imaging techniques for breast MR imaging Magnetic Resonance Imaging Clinics of North America. 2: 511-525. PMID 7489305 |
0.37 |
|
| 1992 |
Chung WS, Hylton NM, Botvinick EH, Schiller NB, Kaufman L. A new magnetic resonance imaging formatting method permits increased visualization of the proximal coronary artery American Journal of Noninvasive Cardiology. 6: 279-284. DOI: 10.1159/000470377 |
0.336 |
|
| 1990 |
Hylton NM, Chung WS, Botvinick EH, Schiller NB, Sheldon P, Kaufman L. Oblique reformatting of multislice magnetic resonance images for improved visualization of coronary arteries Journal of Digital Imaging. 3: 34-37. PMID 2092801 DOI: 10.1007/Bf03168108 |
0.342 |
|
| 1988 |
Crooks LE, Arakawa M, Hylton NM, Avram H, Hoenninger JC, Watts JC, Hale JD, Kaufman L. Echo-planar pediatric imager Radiology. 166: 157-163. PMID 3336674 DOI: 10.1148/Radiology.166.1.3336674 |
0.361 |
|
| 1987 |
Mills TC, Ortendahl DA, Hylton NM, Crooks LE, Carlson JW, Kaufman L. Partial flip angle MR imaging Radiology. 162: 531-539. PMID 3797669 DOI: 10.1148/Radiology.162.2.3797669 |
0.368 |
|
| 1987 |
Crooks LE, Hylton NM, Ortendahl DA, Posin JP, Kaufman L. The value of relaxation times and density measurements in clinical MRI Investigative Radiology. 22: 158-169. PMID 3557889 DOI: 10.1097/00004424-198702000-00014 |
0.408 |
|
| 1987 |
Mills TC, Ortendahl DA, Hylton NM, Carlson JW, Crooks LE, Kaufman L. Variable flip angle excitation for reduced acquisition time magnetic resonance imaging Ieee Transactions On Nuclear Science. 34: 304-308. DOI: 10.1109/Tns.1987.4337353 |
0.368 |
|
| 1987 |
Crooks L, Arakawa M, Hylton N, Avram HE, Hoenninger J, Watts J, Hale J, Kaufman L. Peformance characteristics of an echo planar imager Magnetic Resonance Imaging. 5: 511-512. DOI: 10.1016/0730-725X(87)90389-4 |
0.331 |
|
| 1986 |
Mills TC, Ortendahl DA, Hylton NM. Investigation of partial flip angle magnetic resonance imaging Ieee Transactions On Nuclear Science. 33: 496-500. DOI: 10.1109/Tns.1986.4337151 |
0.382 |
|
| 1985 |
Posin JP, Ortendahl DA, Hylton NM, Kaufman L, Watts JC, Crooks LE, Mills CM. Variable magnetic resonance imaging parameters: effect on detection and characterization of lesions. Radiology. 155: 719-25. PMID 4001375 DOI: 10.1148/Radiology.155.3.4001375 |
0.375 |
|
| 1985 |
Feinberg DA, Mills CM, Posin JP, Ortendahl DA, Hylton NM, Crooks LE, Watts JC, Kaufman L, Arakawa M, Hoenninger JC. Multiple spin-echo magnetic resonance imaging. Radiology. 155: 437-42. PMID 3983396 DOI: 10.1148/Radiology.155.2.3983396 |
0.367 |
|
| 1985 |
Ortendahl DA, Hylton NM, Kaufman L, Crooks LE. Tissue characterization using intrinsic NMR parameters and a hierarchical processing algorithm Ieee Transactions On Nuclear Science. 32: 875-879. DOI: 10.1109/Tns.1985.4336958 |
0.318 |
|
| 1985 |
Feinberg DA, Mills CM, Posin JP, Ortendahl DA, Hylton NM, Crooks LE, Arakawa M, Hoenninger JC, Brant-Zawadzki M. 177 Comparison of Acquired and Synthesized Multiple Spin Echo Magnetic Resonance Images Investigative Radiology. 20. DOI: 10.1097/00004424-198509000-00205 |
0.329 |
|
| 1984 |
Ortendahl DA, Hylton NM, Kaufman L, Crooks LE. Signal to noise in derived NMR images Magnetic Resonance in Medicine. 1: 316-338. PMID 6571562 DOI: 10.1002/Mrm.1910010304 |
0.322 |
|
| 1984 |
Ortendahl DA, Hylton N, Kaufman L, Watts JC, Crooks LE, Mills CM, Stark DD. Analytical tools for magnetic resonance imaging. Radiology. 153: 479-88. PMID 6091173 DOI: 10.1148/Radiology.153.2.6091173 |
0.374 |
|
| 1984 |
Ortendahl DA, Hylton NM, Kaufman L, Crooks LE, Mills CM, Davis PL, Watts JC. 132. Calculation Tools For The Retrospective Evaluation Of Nmr Imaging Procedures Investigative Radiology. 19. DOI: 10.1097/00004424-198409000-00157 |
0.304 |
|
| Show low-probability matches. |